KIR3DL1 and neoplasm: Regarding iKIRs, several studies have reported changing peptide repertoire in tumor cells function as peptide antagonism, which down-modulates NK cell inhibition by reducing inhibitory ligands on tumor cells, caused by low-affinity interaction of KIR-HLA73,74.